AbbVie Inc. (ABBV) News
Follow AbbVie Inc. (ABBV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 187 public stories across 68 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AbbVie Enters Global License Deal With Nxera Pharma for Experimental IBD Drug
AbbVie entered an exclusive global license deal with Nxera Pharma for an experimental inflammatory bowel disease drug.
EQUITY | Nov 04, 2026, 09:56 AM UTC
M
AbbVie to Receive Worldwide IBD Rights to Nxera Pharma Drug
Under an agreement, AbbVie will receive exclusive worldwide rights to develop and commercialize NXE0033744 for inflammatory bowel disease.
MNA | Nov 04, 2026, 08:44 AM UTC
M
Nxera Pharma Sets 2026 Operating Profit Forecast at JPY 15.7 Billion
The company placed its 2026 operating profit forecast at the upper end of its prior range.
EARNINGS | Nov 04, 2026, 06:40 AM UTC
L
AbbVie Expands Oxford R&D Center
AbbVie is expanding its Oxford research and development center.
EQUITY | Nov 04, 2026, 12:02 AM UTC
M
AbbVie Announces Dividend of R$ 0.41712208100 per Unit
AbbVie announced a first-quarter 2027 dividend of R$ 0.41712208100 per unit.
EQUITY | Nov 03, 2026, 08:20 PM UTC
M
AbbVie Reports 2026 Revenue of $17.4B, Net Income of $4.22B
AbbVie reported diluted EPS of $2.37 for the 2026 period. The prior-year figures were revenue of $15.78B, net income of $186M and diluted EPS of $0.1.
EARNINGS | Nov 03, 2026, 06:51 PM UTC
M
AbbVie License Deal With Brise Potentially Valued at $757 Million
EQUITY | Nov 02, 2026, 03:14 PM UTC
M
AbbVie Reports Q3 Revenue of $17.404 Billion, Skyrizi Approved
The headline also reports lutikizumab success, without specifying the nature of that success.
EQUITY | Oct 31, 2026, 07:02 AM UTC
H
Eli Lilly and AbbVie shares hit records after earnings and outlook increases
Shares of Eli Lilly and AbbVie reached new highs Friday after both companies reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks. Lilly was up 3.5% at the time of writing.
EQUITY | Oct 30, 2026, 07:14 PM UTC
M
AbbVie Raises Annual Profit Forecast as Immunology Drugs Fuel Growth
AbbVie lifted its annual profit forecast, citing continued growth from its immunology drugs.
EQUITY | Oct 30, 2026, 04:02 PM UTC
H
AbbVie Reports Q3 2026 Revenue of $17.4 Billion, Up 10.3%
AbbVie said Q3 2026 revenue rose 10.3% year over year to $17.4 billion, in line with estimates. Non-GAAP profit was $3.82 per share, 1.3% above analysts’ consensus.
EQUITY | Oct 30, 2026, 01:32 PM UTC
H
AbbVie Raises FY26 Adjusted EPS Outlook; Boosts Dividend 5.2%
AbbVie raised its adjusted earnings guidance for full-year 2026 while reporting third-quarter results. It also boosted its dividend by 5.2%.
EARNINGS | Oct 30, 2026, 12:20 PM UTC
H
$ABBV AbbVie Q3 Earnings
Adj. EPS $3.82, est. $3.74 Net rev. $17.40B, est. $17.34B Skyrizi rev. $5.78B, est. $5.74B Rinvoq rev. $2.71B, est. $2.70B Humira rev. $683M, est. $679.3M Imbruvica rev. $522M, est. $527.3M Sees FY Adj. EPS $13.95 to $13
EARNINGS | Oct 30, 2026, 11:47 AM UTC
H
AbbVie Neuroscience Revenue Rises 19.4% to $3.39B in Q3
AbbVie reported third-quarter global neuroscience portfolio revenue of $3.39 billion, up 19.4%.
EARNINGS | Oct 30, 2026, 11:46 AM UTC
H
AbbVie Immunology Portfolio Revenue Rises 16.5% to $9.165B in Q3
EARNINGS | Oct 30, 2026, 11:46 AM UTC
H
AbbVie Sees FY Adjusted EPS of $13.95–$13.99
EARNINGS | Oct 30, 2026, 11:46 AM UTC
H
AbbVie reports third-quarter EPS of $2.37
EARNINGS | Oct 30, 2026, 11:46 AM UTC
M
Nxera Pharma Reports Third-Quarter 2026 Results
Nxera Pharma published operational highlights and consolidated results for the third quarter of 2026.
EQUITY | Oct 30, 2026, 06:38 AM UTC
M
AbbVie Q3'26 Earnings Preview: EPS Estimate Is 3.73 USD
AbbVie is set to announce Q3'26 results on October 30 before the market opens. Revenue is estimated at 17.32 billion USD, with EPS anticipated at 3.73 USD.
EQUITY | Oct 29, 2026, 11:00 AM UTC
L
AbbVie Says Qulipta Outperformed Topiramate in Phase 3 Trial
AbbVie reported that Qulipta outperformed topiramate in a Phase 3 migraine prevention trial.
EQUITY | Oct 29, 2026, 10:06 AM UTC
M
Molecular Partners to Cut Nearly Half of Workforce
Swiss biotech firm Molecular Partners plans to cut nearly half of its workforce.
EQUITY | Oct 29, 2026, 09:36 AM UTC
M
AbbVie Drug Reduces Skin-Disease Lesions in Late-Stage Trial
AbbVie said its experimental drug lutikizumab significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease, meeting the main goal of a late-stage study.
EQUITY | Oct 22, 2026, 03:06 PM UTC
M
AbbVie Says Experimental Skin Drug Met Main Goal in Late-Stage Trial
AbbVie said lutikizumab significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease. The late-stage study met its main goal.
EQUITY | Oct 22, 2026, 01:00 PM UTC
M
Wall Street Rises as Healthcare Stocks Rally and Oil Retreats
U.S. main indexes moved higher Tuesday, supported by a surge in healthcare stocks and softer oil prices, extending a recovery from last week's technology-led selloff. Brent crude slipped 1.1% after touching a five-month
EQUITY | Oct 20, 2026, 04:38 PM UTC
L
AbbVie presents ABBV-466 Crohn’s disease data
The company reported higher endoscopic remission rates with its dual-targeting therapy than with either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn’s disease.
EQUITY | Oct 19, 2026, 08:00 AM UTC
H
US Stocks Slide as Hot CPI Lifts Yields and Rate-Hike Bets
September CPI rose 3.7% year over year, above the 3.6% forecast and up from 3.4% in August. By midday, the Nasdaq 100 was down 1.0%, the S&P 500 fell 0.7%, and the 2-year Treasury yield had risen 14 basis points to 4.93%
MACRO | Oct 14, 2026, 03:39 PM UTC
L
AbbVie Says 36% of Crohn’s Trial Patients Achieved Endoscopic Remission on Skyrizi
AbbVie said 36% of patients with Crohn’s disease in a Phase 3 trial achieved endoscopic remission, defined as healing of the intestinal lining with little to no visible inflammation.
EQUITY | Oct 13, 2026, 07:46 PM UTC
M
AbbVie Stock Edges Higher on Positive Lymphoma Trial Data
AbbVie (ABBV) shares saw a slight increase of approximately 0.3% on October 6th following positive results from a clinical trial for its blood-cancer treatment, epcoritamab. The trial indicated that epcoritamab combined
EQUITY | Oct 06, 2026, 07:46 PM UTC
M
Genmab drug epcoritamab reduces lymphoma progression or death risk by 51%
Genmab and AbbVie announced that their drug epcoritamab, when added to standard treatment for newly diagnosed diffuse large B-cell lymphoma, reduced the risk of cancer worsening or death by 51% compared to standard treat
EQUITY | Oct 06, 2026, 12:11 PM UTC
M
European shares rise, Genmab jumps on drug trial results, bond yields dip
European shares climbed towards one-week highs, led by gains in healthcare stocks after Genmab announced upbeat drug-trial results. Euro zone bond yields stabilized after recent gains driven by fiscal and inflation conce
MACRO | Oct 06, 2026, 08:51 AM UTC
M
Genmab Shares Climb on Positive Blood-Cancer Drug Study Results
Genmab shares jumped 8.3% after the company and partner AbbVie announced positive late-stage clinical trial results for their Epkinly drug in a common type of lymphoma. The drug helped extend the time patients lived with
EQUITY | Oct 06, 2026, 08:11 AM UTC
M
STOXX 600 Rises, Driven by Healthcare Gains
Europe's STOXX 600 index (SXXP) is up 0.8%, with significant gains led by healthcare companies. Biotech firm Genmab (GMAB) is a top performer, jumping over 8% to reach a new high.
EQUITY | Oct 06, 2026, 07:55 AM UTC
M
AbbVie, Genmab drug combo shows improved PFS in DLBCL trial
AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The combination d
EQUITY | Oct 06, 2026, 05:34 AM UTC
M
Genmab and AbbVie blood cancer drug combo cuts risk of progression or death
Danish biotech firm Genmab and US drugmaker AbbVie announced that their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. S
EQUITY | Oct 05, 2026, 10:09 PM UTC
M
Abbvie Discloses $216 Million In Q3 2026 R&D, Milestone Expenses
AbbVie Inc. reported that its Q3 2026 GAAP and adjusted earnings included $216 million in expenses for acquired intellectual property rights and milestones.
EQUITY | Oct 05, 2026, 10:09 PM UTC
H
AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense
AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense
LIVE | Oct 05, 2026, 08:14 PM UTC
H
AbbVie, Genmab drug combo cuts lymphoma progression or death risk in study
AbbVie (ABBV) and Genmab (GMAB) reported that their combination treatment for newly diagnosed lymphoma patients reduced the risk of disease progression or death in a late-stage study. The news sent Genmab shares up about
EQUITY | Oct 05, 2026, 07:36 PM UTC
H
Genmab, AbbVie drug shows PFS improvement in DLBCL trial
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial. The trial evaluated fixed treatment duration epcoritamab in combination with rituximab and standard of care, demonstrating a sta
EQUITY | Oct 05, 2026, 06:50 PM UTC
M
AbbVie Schedules Q3 2026 Earnings Call
AbbVie has announced it will host its third-quarter 2026 earnings conference call.
EQUITY | Oct 01, 2026, 12:01 PM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Key facts: Juvmo +1.7 hrs controlled; AbbVie (ABBV) partners Valkai AI
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
NEWS | Sep 30, 2026, 07:01 AM UTC
L
AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study
WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis.All three dose regimens met the study's primary endpo
NEWS | Sep 30, 2026, 06:29 AM UTC
L
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval
AbbVie NYSE:ABBV, the immunology and neuroscience drugmaker, secured FDA approval for Juvmo, a once-daily Parkinson's treatment. Its shares dropped nearly 0.8% to $264.29 at 10.10 EST time on Tuesday, September 29. The a
REGULATION | Sep 29, 2026, 04:21 PM UTC
L
AbbVie Partners With Valkai To Advance AI-powered Clinical Research
WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV), a pharmaceutical company, announced a partnership with Valkai, a life sciences artificial intelligence platform, to enhance its AI infrastructure and accelerate scientific inno
NEWS | Sep 29, 2026, 01:39 PM UTC
L
AbbVie Inc. (ABBV) Partners With Valkai to Apply AI in Clinical Development
AbbVie entered a partnership with Valkai to deploy AI tools across targeted areas of clinical research to improve efficiency, speed insights and support opportunities to reduce development timelines.Material DetailsConte
NEWS | Sep 29, 2026, 01:01 PM UTC
L
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
NORTH CHICAGO, Ill., Sept. 29, 2026 // -- AbbVie (NYSE:ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate
NEWS | Sep 29, 2026, 01:00 PM UTC
L
AbbVie Just Won an FDA First in Parkinson's Disease
AbbVie (ABBV, Financials) won U.S. Food and Drug Administration approval for Juvmo, giving the pharmaceutical company a new Parkinson's disease treatment with a differentiated mechanism.The FDA approved Juvmo, also known
REGULATION | Sep 28, 2026, 03:18 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
AbbVie Announces FDA Approval Of JUVMO For Parkinson's Disease
WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced the FDA has approved JUVMO tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease. The approval is supported by
REGULATION | Sep 28, 2026, 12:34 PM UTC
L
AbbVie Gets FDA OK of Juvmo for Parkinson's Disease
By Colin KellaherAbbVie has won U.S. Food and Drug Administration approval of its Juvmo once-daily oral treatment for the progressive neurological disorder Parkinson's disease.AbbVie on Monday said the green light makes
REGULATION | Sep 28, 2026, 12:31 PM UTC
L
AbbVie Inc. (ABBV) Wins FDA Approval For JUVMO In Parkinson's
AbbVie Inc. received U.S. FDA approval for JUVMO (tavapadon) tablets, a selective D1/D5 receptor agonist, for adult Parkinson's disease. The company expects U.S. availability in October 2026.Material DetailsContext by AI
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
NORTH CHICAGO, Ill., Sept. 28, 2026 // -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist
REGULATION | Sep 28, 2026, 12:00 PM UTC
L
Weekly Recap: FDA approval for Parkinson’s therapy and Enchant v3 AI pact
AbbVie, Inc. (NYSE:ABBV) is expanding its footprint across therapies and tech—winning FDA approval for a Parkinson’s drug and Canadian approval for Epkinly while launching Allergan Aesthetics’ SKIN360 and partnering with
GEOPOLITICS | Sep 28, 2026, 11:06 AM UTC
L
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Biotech dealmaking this week was lighter on blockbuster takeovers than earlier in 2026, but the tape was busy: Eli Lilly, Novo Nordisk, Novartis and AbbVie used licenses and research pacts to buy access to platforms rath
NEWS | Sep 26, 2026, 01:03 AM UTC
L
US FDA approves AbbVie's drug for Parkinson's disease
The US Food and Drug Administration has approved AbbVie's NYSE:ABBV drug for Parkinson's disease in adults, the health regulator's website showed on Friday.
REGULATION | Sep 25, 2026, 10:00 PM UTC
L
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO
Shares of ADARx Pharmaceuticals (ADRX.O) rose 30% above their initial public offering price on Friday after the late-stage gene therapy developer raised $446.3 million in an upsized US initial public offering.The shares
EQUITY | Sep 25, 2026, 04:21 PM UTC
L
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals (ADRX.O) said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings.The San Diego-based drug developer sold 26.
EQUITY | Sep 25, 2026, 11:02 AM UTC
L
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
AbbVie NYSE:ABBV, the drugmaker behind major immunology, neuroscience and cancer medicines, added Iambic's AI platform to its small-molecule drug discovery work. Shares stays flat at around $265 at 11.34am ET time on Thu
EQUITY | Sep 24, 2026, 07:41 PM UTC
L
RBC says AI weakness appears to be fueling biotech rally
RBC SAYS AI WEAKNESS APPEARS TO BE FUELING BIOTECH RALLYWeakness in artificial intelligence-related stocks may be helping fuel a biotech rally as investors shift money from volatile technology shares into healthcare stoc
EQUITY | Sep 23, 2026, 01:15 PM UTC
L
ABBV - Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
ABBV - Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
NEWS | Sep 22, 2026, 12:01 PM UTC